On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 9, 2012, Pages 1949-1951

  Matsuura, E ^a   Guyer, K ^b   Yamamoto, H ^c   Lopez, L R ^d   Inoue, K ^e  

^a OKAYAMA UNIVERSITY   (Japan)

^b INDIANA UNIVERSITY SOUTH BEND   (United States)

^c KURASHIKI CENTRAL HOSPITAL   (Japan)

^d Division of Medicine   (United States)

^e KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CREATININE;

ACUTE CORONARY SYNDROME; AGED; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE LEVEL;

ACUTE CORONARY SYNDROME; ASPIRIN; HUMANS; THROMBOXANE B2;

EID: 84865730125     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04845.x     Document Type: Letter

References (9)

1. Patrono C, Garcia-Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
2. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with antiplatelet inhibitory drugs. Blood 1987; 69: 180-6.
3. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-64S.
4. Hankle GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17.
5. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-90.
6. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
7. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg G, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KAA, Topol EJ. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid. Determinants and effects on cardiovascular risk. Circulation 2008; 118: 1705-12.
8. Russo I, Frascaroli C, Mattiello L, Viretto M, Barale C, Doronzo G, DiMartino L, Trovati M, Anfossi G. Aspirin resistance subjects present a pro-inflammatory milieu with an increased oxidative stress: in these conditions, high glucose fails to influence platelet response to agonists. Diabetologia 2011; 54(Suppl. 1): S36.
9. Ames PRJ, Batuca JR, Muncy IJ, Garcia De La Torre I, Pascoe-Gonzales S, Guyer K, Matsuura E, Lopez LR. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. Thromb Res 2012; doi:10.1016/j.thromres.2012.03.025.